EE200100026A - Oksasolidinoonid silmahaiguste raviks - Google Patents

Oksasolidinoonid silmahaiguste raviks

Info

Publication number
EE200100026A
EE200100026A EEP200100026A EEP200100026A EE200100026A EE 200100026 A EE200100026 A EE 200100026A EE P200100026 A EEP200100026 A EE P200100026A EE P200100026 A EEP200100026 A EE P200100026A EE 200100026 A EE200100026 A EE 200100026A
Authority
EE
Estonia
Prior art keywords
treatment
oxazolidinones
eye diseases
oxazolidinone
treating
Prior art date
Application number
EEP200100026A
Other languages
English (en)
Inventor
Cochran Robert
W. Ford Charles
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of EE200100026A publication Critical patent/EE200100026A/et

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
EEP200100026A 1998-07-14 1999-07-07 Oksasolidinoonid silmahaiguste raviks EE200100026A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9276598P 1998-07-14 1998-07-14
PCT/US1999/012367 WO2000003710A1 (en) 1998-07-14 1999-07-07 Oxazolidinones to treat eye infections

Publications (1)

Publication Number Publication Date
EE200100026A true EE200100026A (et) 2002-06-17

Family

ID=22235050

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100026A EE200100026A (et) 1998-07-14 1999-07-07 Oksasolidinoonid silmahaiguste raviks

Country Status (27)

Country Link
US (2) US6337329B1 (et)
EP (1) EP1096934B1 (et)
JP (1) JP2002520359A (et)
KR (1) KR20010079530A (et)
CN (1) CN1305374A (et)
AT (1) ATE304886T1 (et)
AU (1) AU740781B2 (et)
BG (1) BG64666B1 (et)
BR (1) BR9912004A (et)
CA (1) CA2334811A1 (et)
DE (1) DE69927380T2 (et)
DK (1) DK1096934T3 (et)
EA (1) EA003274B1 (et)
EE (1) EE200100026A (et)
ES (1) ES2249020T3 (et)
HU (1) HUP0102836A3 (et)
ID (1) ID27276A (et)
IL (1) IL140769A0 (et)
NO (1) NO20010202D0 (et)
NZ (1) NZ509375A (et)
PL (1) PL345544A1 (et)
PT (1) PT1096934E (et)
SG (1) SG125079A1 (et)
SK (1) SK20332000A3 (et)
TR (1) TR200100066T2 (et)
WO (1) WO2000003710A1 (et)
ZA (1) ZA200100038B (et)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR020660A1 (es) * 1998-09-30 2002-05-22 Alcon Lab Inc Composiciones antibioticas para el tratamiento de ojos, oidos y nariz
CA2384717C (en) * 1999-09-13 2010-07-27 Insite Vision Incorporated Topical treatment for prevention of ocular infections
US6562820B2 (en) 2000-07-05 2003-05-13 Pharmacia & Upjohn Company Method for treatment and prevention of mastitis
PE20020300A1 (es) * 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US20030069235A1 (en) * 2001-09-14 2003-04-10 J. Greg Slatter Treatment for ocular infections
US20040019012A1 (en) * 2002-02-22 2004-01-29 Singh Satish K. Ophthalmic antibiotic drug formulations containing a cyclodextrin compound and cetyl pyridinium chloride
TW201043267A (en) * 2009-03-19 2010-12-16 Intervet Int Bv In situ constituting a vaccine for administration to a predetermined herd of animals
CN101766628B (zh) * 2010-01-20 2012-07-04 广东宏盈科技有限公司 一种眼科外用抗细菌感染药物
US10149885B2 (en) 2012-09-13 2018-12-11 Starpharma Pty Limited Method of treatment or prophylaxis of infections of the eye

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5164510A (en) * 1988-09-15 1992-11-17 The Upjohn Company 5'Indolinyl-5β-amidomethyloxazolidin-2-ones
US5231188A (en) * 1989-11-17 1993-07-27 The Upjohn Company Tricyclic [6.5.51]-fused oxazolidinone antibacterial agents
JP3176626B2 (ja) * 1991-11-01 2001-06-18 ファルマシア・アンド・アップジョン・カンパニー 抗菌剤として有用な置換アリール−およびヘテロアリールフェニルオキサゾリジノン類
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
DE69419523T2 (de) 1993-11-22 1999-11-25 Upjohn Co Substituierte hydroxyacetyl piperazine phenyl oxazolidinonsäureester
DE4425612A1 (de) * 1994-07-20 1996-04-04 Bayer Ag 6-gliedrige stickstoffhaltige Heteroaryl-oxazolidinone
DE4425613A1 (de) * 1994-07-20 1996-01-25 Bayer Ag 5-gliedrige Heteroaryl-oxazolidinone
PL330240A1 (en) * 1996-05-31 1999-05-10 Scripps Research Inst Methods and compositions useful in inhibiting angiogenesis in which alphavbeta5 acts as intermediary

Also Published As

Publication number Publication date
EP1096934A1 (en) 2001-05-09
IL140769A0 (en) 2002-02-10
NO20010202L (no) 2001-01-12
ES2249020T3 (es) 2006-03-16
US6337329B1 (en) 2002-01-08
EA003274B1 (ru) 2003-04-24
EA200100133A1 (ru) 2001-06-25
AU740781B2 (en) 2001-11-15
PT1096934E (pt) 2005-11-30
HUP0102836A3 (en) 2003-12-29
SG125079A1 (en) 2006-09-29
TR200100066T2 (tr) 2001-05-21
ZA200100038B (en) 2002-01-02
JP2002520359A (ja) 2002-07-09
AU4953099A (en) 2000-02-07
PL345544A1 (en) 2001-12-17
US6740652B2 (en) 2004-05-25
DE69927380T2 (de) 2006-07-06
CA2334811A1 (en) 2000-01-27
ATE304886T1 (de) 2005-10-15
DK1096934T3 (da) 2005-11-28
NO20010202D0 (no) 2001-01-12
BG64666B1 (bg) 2005-11-30
KR20010079530A (ko) 2001-08-22
ID27276A (id) 2001-03-22
SK20332000A3 (sk) 2001-05-10
BG105142A (en) 2001-10-31
BR9912004A (pt) 2001-04-10
HUP0102836A2 (hu) 2002-05-29
CN1305374A (zh) 2001-07-25
WO2000003710A1 (en) 2000-01-27
NZ509375A (en) 2003-11-28
US20020065280A1 (en) 2002-05-30
DE69927380D1 (de) 2005-10-27
EP1096934B1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
DK1574209T3 (da) Fremgangsmåde til behandling af ophthalmiske sygdomme
DK0867178T3 (da) Non-allosteriske GABA A agonister til behandling af søvnforstyrrelser
DK1140170T3 (da) Antistoffragmenter til topisk behandling af öjensygdomme
ATE457171T1 (de) Kombinationstherapie substituierter oxazolidinone
LU91928I2 (fr) Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
ATE395923T1 (de) Prophylaktische und therapeutische behandlung von infektiösen, autoimmunen und allergischen krankheiten mit verbindungen, die auf monosacchariden basieren
DE59802356D1 (de) Lagerstabile ophthalmische zusammensetzungen, umfassend diclofenac und ofloxacin
ATE254461T1 (de) Behandlung von augenschmerzen
EE200100026A (et) Oksasolidinoonid silmahaiguste raviks
ATE110957T1 (de) Pharmazeutische behandlung einer augenentwicklung.
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
DK1305037T3 (da) Smertestillende medikament
DE69912304D1 (de) Verwendung von staurosporine derivaten zur behandlung von okularen neovaskularen erkrankungen
SE9403160D0 (sv) Method and means for prevention and treatment of secondary cataract
BR0113646A (pt) Tratamento de distúrbios inflamatórios
EA200100010A1 (ru) Местное применение оксазолидинонов для трансдермальной доставки
DK0900085T3 (da) Behandling af overdreven aggression med olanzapin
RU98118275A (ru) Способ лечения внутриглазной инфекции